In Depth Research on Histone Deacetylase Inhibitors Market & Pipeline Insight2015

"Histone Deacetylase (HDAC) Inhibitors Market & Pipeline Insight 2015" Report Highlights:

* Introduction & Classification Histone Deacetylase (HDAC) Inhibitors
* Mechanism of Histone Deacetylase (HDAC) Inhibitors
* Histone Deacetylase (HDAC) Inhibitors Market Dynamics
* Global Histone Deacetylase (HDAC) Inhibitor Market Outlook
* Histone Deacetylase (HDAC) Inhibitor Clinical Pipeline by Company, Indication & Phase
* Histone Deacetylase (HDAC) Inhibitor Clinical Pipeline: 63
* Majority of Histone Deacetylase (HDAC) Inhibitor in Preclinical Phase: 35
* Marketed Histone Deacetylase (HDAC) Inhibitors: 3 (Beleodaq, Istodax & Zolinza)

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-Histone-Deacetylase-Inhibitors-Market-&-Pipeline-Insight2015.php

Table of Contents

1. Introduction to Histone Deacetylase (HDAC) Inhibitors

2. Classification of Histone Deacetylase (HDAC)
2.1 Class I HDAC
2.2 Class IIa HDAC
2.3 Class IIb HDAC
2.4 Class IV HDAC

3. Classification of Histone Deacetylase (HDAC) Inhibitors
3.1 Hydroxamates
3.2 Cyclic Peptides
3.3 Aliphatic Acids
3.4 Benzamides

4. Mechanism of Histone Deacetylase (HDAC) Inhibitors

5. Global Histone Deacetylase (HDAC) Inhibitor Market Outlook
5.1 Curent Market Scenario
5.2 Histone Deacetylase (HDAC) Pipeline Overview

6. Histone Deacetylase (HDAC) Inhibitors Market Dynamics
6.1 Favorable Market Parameters
6.2 Commercialization Challenges

7. Histone Deacetylase (HDAC) Inhibitors Future Prospects

8. Histone Deacetylase (HDAC) Inhibitor Clinical Pipeline by Company, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-III
8.7 Registered

9. Marketed Histone Deacetylase (HDAC) Inhibitor Clinical Insight by Company & Indication
9.1 Belinostat (Beleodaq)
9.2 Romidepsin (Istodax)
9.3 Vorinostat (Zolinza)

10. Discontinued & Suspended Histone Deacetylase (HDAC) Inhibitor Clinical Insight
10.1 No Development Reported
10.2 Discontinued
10.3 Suspended

11. Competitive Landscape
11.1 4SC
11.2 Acetylon Pharmaceuticals
11.3 Astellas Pharma
11.4 Celleron Therapeutics
11.5 Chipscreen Biosciences
11.6 Chroma Therapeutics
11.7 Chong Kun Dang Pharmaceutical
11.8 CrystalGenomics
11.9 Curis
11.10 Digna Biotech
11.11 Evgen
11.12 Johnson & Johnson Pharmaceutical Research and Development
11.13 Italfarmaco
11.14 MEI Pharma
11.15 Mirati Therapeutics
11.16 Novartis
11.17 Onxeo
11.18 Orchid Chemicals and Pharmaceuticals
11.19 Pharmacyclics
11.20 Repligen
11.21 TetraLogic Pharmaceuticals

Figure 1-1: Properties of HDAC
Figure 1-2: Therapeutic Utility of HDAC Inhibitors
Figure 1-3: Benefits of HDAC Inhibitors
Figure 1-4: Limitation of HDAC Inhibitors
Figure 2-1: Classification of HDAC
Figure 3-1: Classification of HDAC Inhibitors
Figure 4-1: Mechanism of Vorinostat
Figure 4-2: Mechanism of Panobinostat
Figure 4-3: Mechanism of Resminostat
Figure 4-4: Mechanism of Entinostat
Figure 5-1: Histone Deacetylase (HDAC) Pipeline by Phase (%), 2015
Figure 5-2: Histone Deacetylase (HDAC) Pipeline by Phase (Number), 2015
Figure 5-3: Discontinued Histone Deacetylase (HDAC) Pipeline by Phase (%), 2015
Figure 5-4: Discontinued Histone Deacetylase (HDAC) Pipeline by Phase (Number), 2015
Figure 6-1: HDAC Inhibitors Market Favorable Parameters
Figure 6-2: HDAC MarketCommercialization Challenges
Figure 11-1: 4SC Clinical Pipeline
Figure 11-2: Celleron Therapeutics Clinical Pipeline
Figure 11-3: Curis Clinical Pipeline
Figure 11-4: DIGNA Biotech Clinical Pipeline
Figure 11-5: Onxeo Clinical Pipeline
Figure 11-6: TetraLogic Pharmaceuticals Clinical Pipeline

List of Tables

Table 1-1: Few Important HDACi under Development for Different Indications
Table 3-1: HDAC Inhibitors Belonging to Different Classes
Table 4-1: FDA Approved HDACi for Lymphoma

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.